No images? Click here [link removed]

Welcome to The Corner. In this issue, we look at the BIOSECURE Act, and how it fails to address chokepoints and dangerous dependencies in the supply of vital drugs. We also look at the DOJ’s transformative victory in the Google search case.

BIOSECURE Act Aimed at Curbing China’s Role in U.S. Drug Supply Does Little to Address Shortages or Dependencies

Garphil Julien

One of President Biden’s legislative priorities before he leaves office is likely the passage of the bipartisan BIOSECURE Act. The bill, introduced in January by Republican Congressman Mike Gallagher and Democratic Congressman Raja Krishnamoorthi, aims to help break U.S. dependency on Chinese pharmaceutical manufacturers by restricting certain partnerships with U.S. biotech companies. But while a key goal of the bill is to prevent the weaponization [[link removed]] of pharmaceutical supply chains, the bill fails to address U.S. access to critical pharmaceutical materials. It also does little to address the closely related problem of acute drug shortages.

Today, many U.S. manufacturers and distributors rely on single-source suppliers of pharmaceutical ingredients, with 83 of the top 100 [[link removed]] generic medicines produced in the U.S. sourcing ingredients from a single location offshore. These locations are often in China and many Chinese drugmakers have monopolies over the production of critical ingredients needed for these drugs. Any disruption or slowdown in their manufacturing process, as has happened in the past, can reduce or even cut entirely the global production of key pharmaceuticals.

China is the sole source for about 20% [[link removed].] of the total ingredients in our most vital medicines and 45% of key starting materials. The U.S. is heavily reliant on China for the supply of drugs that treat a host of illnesses and conditions including but not limited to obesity, blood pressure, trachoma, blood clots, cancers, bacterial infections, cystic fibrosis, HIV, dementia, diabetes, and neutropenia. The current shortage of antibiotic Penicillin G Benzathine, which is fueling concerns of a major public health crisis [[link removed]], is due to failure by monopolistic suppliers in China to increase production. These suppliers control three of the four factories [[link removed]'s%20role%20in%20the%20supply,cause%20of%20the%20current%20shortage.] in the world that produce ingredients for the drug.

The BIOSECURE Act also comes as shortages of critical medicines hit an all-time high this summer in the U.S. According to the American Society of Health Care Pharmacists, a total of 323 drugs were in short supply, breaking a record [[link removed]] set in 2014 and up 86% from its 10-year low of 174 in 2017. This year’s total includes 66 first-time drug shortages.

The BIOSECURE Act aims to identify “biotechnology companies of concern,” a designation which would prevent [[link removed]] manufacturers from receiving U.S. government contracts or grants from sourcing any material or service from these concerned entities. While the act also claims it will prevent the weaponization of pharmaceutical supply chains, its narrow definition of reasons for “concern” does not include concentration of production in a single location or instances where a producer is a single or sole-source supplier to other manufacturers that serve the U.S.

An example of why this point is so important are China and India’s actions on pharmaceuticals during the Covid pandemic. At the onset of the crisis in 2020, India placed export bans [[link removed]] on a total of 26 pharmaceutical ingredients and their formulations, including antibiotics. In total, India supplies nearly half [[link removed].] of generic drugs for the U.S. In 2022 as a result of China’s mandatory Covid lockdowns, GE Healthcare’s plant in Shanghai stopped [[link removed]] producing the CT scan contrast agent Omnipaque. One result was a disruption in the U.S. of the ability to measure arterial blockages, identify heart conditions, and spot cancerous tumors.

In many respects, the situation continues to get worse. Over the last decade in the United States, there has been an 18% decrease [[link removed]-] in the number of manufacturing facilities producing active pharmaceutical ingredient, or APIs. Just between 2019 and 2023, the number of plants fell 10%. [[link removed]] During this same period, China continued to add new facilities, increasing the total number of API plants by 55 percent.

While the BIOSECURE Act may promote some diversification of production, simply limiting Chinese control over new drugs does not get at the most pressing and immediate threats. Most of the pharmaceutical supply chain is still hyperconcentrated, and this continues to pose a variety of threats, including to U.S. national security, the day-to-day supply of vital drugs, and to the taxpayers and patients who must still pay outrageous prices for monopolized medicines.

Open Markets Applauds Judge’s Decision Deeming Google a Monopoly

The Open Markets Institute last week welcomed a Court decision that Google violated the Sherman Act by illegally maintaining its monopoly in general online search and search text advertising. The case was the first of two that have been filed by the Department of Justice against Google. Executive director Barry Lynn said “The Google Search ruling was a long time coming and is a historic win for our antitrust enforcers and internet users everywhere,” Center for Journalism & Liberty director Dr. Courtney Radsch also weighed in, saying, “Google's threats to censor journalism and prevent news publishers from accessing its monopoly must be met with swift and decisive action from all those who care about a free press and democracy." The Washington Post [[link removed]] quoted Lynn on the decision as saying, “For a long time, Google was regarded as untouchable. This is the most powerful corporation perhaps in human history.” PC Magazine [[link removed]] quoted from the statement issued by Open Markets.

Senior reporter Karina Montoya published an article in Tech Policy Press [[link removed]] offering a breakdown of the key points from the nearly 300-page decision by Judge Amit Mehta. Montoya notes that a key point in the decision was that a monopoly in one market can beget monopolies in others, writing, “Default distribution also enabled Google to monopolize another market: search text ads, which are displayed as links on search results in response to users’ queries — the foundation of Google’s ad search business.” Open Markets’ policy counsel Tara Pincock also commented on the ruling in The Washington Post [[link removed]] and in Ars Technica [[link removed]]. Pincock played a key role in drafting one of the early iterations of the case, which developed out of an investigation of Google by 50 state attorneys general. Meanwhile, senior legal analyst Daniel Hanley was quoted in The Daily Upside [[link removed]]on the case.

Open Markets Closely Follows Trial to Stop Major Network Sports Cartel

The Open Markets Institute last week closely followed the opening of a trial to prevent the launch of a sports streaming service called Venu Sports. The service — which is owned by Disney/ESPN, Warner Bros. Discovery, and Fox — would control some 80 percent of the national market for live sports broadcasts. OMI reporter Austin Ahlman attended the New York-based trial, which was based on a suit by sports streaming service Fubo. Ahlman laid out the stakes in an article in Common Dreams [[link removed]]. “With that market power, these giants could destroy what remains of the cable television market and stifle competition in the market for live programmatic streaming services before it fully gets off the ground.” He also wrote about Fubo’s complaint in the Corner [[link removed]] and gave live updates [[link removed]] on X. Open Markets also joined partner organizations in filing an amicus brief [[link removed]] on behalf of Fubu.

Open Markets Comments on USDA’s Proposed Reforms to Poultry Tournament Systems

Open Markets Institute food program manager Clare Kelloway submitted a comment [[link removed]] to the U.S. Department of Agriculture in support of the agency’s proposed reforms to poultry tournament payment system. Kelloway also proposed additional actions that would allow USDA to better enforce the Packers and Stockyards Act against powerful chicken processing companies, improve fair competition in the poultry market, and help independent growers remain viable. In addition to ensuring fair base pay rates, OMI suggests that the USDA limit the portion of pay that can come from performance-related bonuses; ensure that poultry contracts are long enough for farmers to pay off additional capital investments demanded by chicken companies, and establish certain thresholds to guarantee growers a non-comparison-based payment option if they desire. Read the full comment here [[link removed]].

📝 WHAT WE'VE BEEN UP TO: The American Prospect [[link removed]] quoted Center for Journalism and Liberty director Dr. Courtney Radsch on the loss of news programming amid the growing trend in streaming networks. “It’s already not very profitable to run a news outlet on cable or broadcast,” she said. “I don’t think policymakers are either addressing the current challenges adequately nor are they looking to the history of governing our information communication technology. We’ve got to get on top of this faster and not wait two decades.”

Open Markets Institute’s legal director Sandeep Vaheesan was quoted in The American Prospect [[link removed]] in an article on private equity investors entering the college sports market. “You’d think if they’re so worried about the financial burden of paying players, [colleges] wouldn’t want to auction off another portion of the revenue to Wall Street,” Vaheesan said.

Vaheesan gave an interview to PlayerFM [[link removed]]’s podcast Money on the Left [[link removed]] to discuss his upcoming book Democracy in Power: A History of Electrification in the United States. On the podcast he spoke about the need to transition from a carbon-based energy industry dominated by a few private players to one powered by publicly owned clean energy.

CJL’s Dr. Radsch was quoted in a report from Aspen Digital [[link removed]]discussing the harmful impact AI poses to local news outlets as big AI players seek partnerships with larger news organizations, leaving smaller outlets to fend for themselves. “How do smaller newsrooms afford to use some of these technologies?” Radsch said. “And does using them just entrench the power of the large platforms that control these tools?”

The Orange County Register [[link removed]] reprinted a quote OMI legal director Sandeep Vaheesan gave to the New York Times [[link removed]] on algorithmic price-fixing by RealPage, which helps landlords collude to set rent. Vaheesan said the government can utilize their legal advantage over private attorneys through civil investigative demands that “pop open the hood” on RealPage’s software, analyzing how its algorithm works before going to court.

🔊 ANTI-MONOPOLY RISING:

Video game distribution giant Valve is facing a federal class action antitrust lawsuit in Seattle over alleged abuses of its market power relating to its practices that restrict publishers’ ability to offer their games at lower prices through competing distributors. ( Reuters [[link removed]])

Several federal agencies, including the Federal Communications Commission and the Federal Trade Commission, teamed up to roll out a “Time is Money” initiative aimed at cracking down on exploitative practices that force consumers to waste significant amounts of time on basic tasks like canceling subscriptions and accessing product information and services. ( Associated [[link removed]] Press [[link removed]])

The Department of Justice is suing TikTok on behalf of the FTC for alleged violations of the Children’s Online Privacy Protection Act’s regulations on the collection and use of data from minors under the age of 13. The FTC has had a consent order with TikTok dating back to 2019 for its repeated violations of the law. ( Security [[link removed]] Magazine [[link removed]])

We appreciate your readership. Please consider making a contribution to support the continued publication of this newsletter.

DONATE [[link removed]] 📈 VITAL STAT: $35 Billion

The value of a proposed merger between chip design software giants Synopsys and Ansys. The deal is under investigation by the UK’s Competition and Markets Authority over concerns the deal will dramatically shrink competition in a key part of the microchip development chain. ( CIO [[link removed]])

📚 WHAT WE'RE READING:

The Art of Power [[link removed]]: Former House speaker Nancy Pelosi recounts her time guiding the caucus through some of the most consequential political and legislative fights in modern history. One reason the book is important for the competition community is Pelosi’s account of shepherding through Congress several of President Biden’s pathbreaking initiatives to break offshore chokepoints. These include the American Rescue Plan, the Inflation Reduction Act, and the CHIPS and Science Act.

🔎 TIPS? COMMENTS? SUGGESTIONS?

We would love to hear from you—just reply to this e-mail and drop us a line. Give us your feedback, alert us to competition policy news, or let us know your favorite story from this issue.

SUBSCRIBE TO OUR NEWSLETTER [[link removed]] DONATE [[link removed]] Share [link removed] Tweet [link removed] Share [[link removed]] Forward [link removed]

Open Markets Institute

655 15th St NW, Suite 800, Washington, DC xxxxxx

We thought you'd like to be in the know about competition policy news. Liked what you read? Please forward to a friend or colleague.

Written and edited by: Barry Lynn, Austin Ahlman, Ezmeralda Makhamreh, and Anita Jain.

Preferences [link removed] | Unsubscribe [link removed]